Back to Search
Start Over
Busulfan, melphalan, and bortezomib compared to melphalan as a high dose regimen for autologous hematopoietic stem cell transplantation in multiple myeloma: long term follow up of a novel high dose regimen
- Source :
- Leuk Lymphoma
- Publication Year :
- 2020
- Publisher :
- Informa UK Limited, 2020.
-
Abstract
- Melphalan at a dose of 200 mg/m(2) (MEL200) remains the standard high dose therapy before autologous stem cell transplantation (ASCT) for multiple myeloma (MM). Intensifying the high dose regimen has shown promising results. We report here 7-year follow up of our novel high dose regimen of busulfan and melphalan followed by bortezomib (BuMelVel). Forty-three MM patients received BuMelVel high dose therapy with pharmacokinetic adjusted busulfan. Outcomes were compared to a matched control cohort from the CIBMTR database (n = 162) receiving MEL200. The primary endpoint was progression free survival. Five year PFS was 47% v 30% (95% CI; 32–62) in favor or the BuMelVel group (95% CI; 23–37) (p=0.05). In multivariate analysis for PFS, BuMelVel (HR 0.65; 95% CI 0.44–0.97)(p=0.036) was predictive. Similar to recent reports of double alkylator therapy, although depth of response was similar between the BuMelVel group and MEL200, the BUMELVEL group experienced an improved PFS.
- Subjects :
- Melphalan
Oncology
Cancer Research
medicine.medical_specialty
Transplantation Conditioning
Long term follow up
medicine.medical_treatment
Hematopoietic stem cell transplantation
Transplantation, Autologous
Article
Bortezomib
03 medical and health sciences
0302 clinical medicine
Autologous stem-cell transplantation
immune system diseases
hemic and lymphatic diseases
Internal medicine
Antineoplastic Combined Chemotherapy Protocols
Humans
Medicine
Busulfan
Multiple myeloma
business.industry
Hematopoietic Stem Cell Transplantation
Hematology
medicine.disease
Regimen
surgical procedures, operative
030220 oncology & carcinogenesis
Multiple Myeloma
business
Follow-Up Studies
030215 immunology
medicine.drug
Subjects
Details
- ISSN :
- 10292403 and 10428194
- Volume :
- 61
- Database :
- OpenAIRE
- Journal :
- Leukemia & Lymphoma
- Accession number :
- edsair.doi.dedup.....d2c7b999191e8784f0d1f5faf912082a